Deutsch Website, wo Sie Qualität und günstige https://medikamenterezeptfrei2014.com/ Viagra Lieferung weltweit erwerben.

Ein wenig Kopfschmerzen, aber schnell verging der Schmerz. Gefühle, die ich erlebte ein unvergessliches priligy kaufen Ehrlich gesagt nicht wirklich glauben, in der Kraft Viagra. Setzte nach der Anleitung. Das Ergebnis ist natürlich, sich selbst rechtfertigte.

Wissenschaftliche publikationen

Wissenschaftliche Publikationen


Auswahl seit 1993 aus über 900 Veröffentlichungen
1. Spengler et al.: Differential signal transduction patterns of five splice variants of the PACAP receptor.
Nature 365: 170-175 (1993)
2. Rupprecht at al.: Progesterone receptor mediated effects of neuroactive steroids. Neuron 11:
523-530 (1993)
3. Trapp et al.: Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new
principle of glucocorticoid action in the central nervous system. Neuron 13: 1-6 (1994)
4. Wiegers et al.: Glucocorticoids accelerate anti-T-cell receptor-induced T-cell growth. Journal of
Immunology 155: 1893-1902 (1995)
5. Lauer et al.: In quest of identifying vulnerability markers for psychiatric disorders by all-night
polysomnography. Archives of General Psychiatry 52: 145-153 (1995)
6. Linthorst et al.: Effect of bacterial endotoxin and interleukin-1ß on hippocampal serotonergic
neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study.
Journal of Neuroscience 15:2920-2934 (1995)
7. Holsboer and Barden: Antidepressants and HPA regulation. Endocrine Reviews 17: 187-205 (1996)
8. Patchev et al.: Neonatal treatment of rats with the neuroactive steroid tetrahydro-
deoxycorticosterone (THDOC) abolishes the behavioural and neuroendocrine consequences of adverse
early life events. The Journal of Clinical Investigations 99: 962-966 (1997)
9. Timpl et al.: Impaired stress response and reduced anxiety in mice lacking a functional
corticotropin-releasing hormone receptor 1. Nature Genetics 19: 162-166 (1998)
10. Rupprecht and Holsboer: Neuroactive steroids: mechanisms of action and
neuro-psychopharmacological perspectives. Trends in Neuroscience 22: 410-416 (1999)
11. Behl and Holsboer: The female sex hormone estrogen as neuroprotectant: an actor on different
stages. Trends in Pharmacological Sciences, 20: 441-444 (1999)
12. Hrabé de Angelis et al.: Genome-wide, large-scale production of mutant mice by ENU mutagenesis.
Nature Genetics 25: 444-447 (2000)
13. Holsboer: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology
23:477-501 (2000)
14. Holsboer: Antidepressant drug discovery in the postgenomic era. World Journal of Biological
Psychiatry 2:165-177 (2001)
15. Keck et al.: The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate
emotionality in rats. European Journal of Neuroscience 13:373-380 (2001)
16. Gesing et al.: Psychological stress increases hippocampal mineralocorticoid receptor levels:
involvement of corticotropin-releasing hormone. Journal of Neuroscience 21:4822-4829 (2001)
17. Sillaber et al.: Enhanced and delayed stress-induced alcohol drinking in mice lacking functional
CRH1 receptors. Science 296:931-933 (2002)
18. Keck et al.: Vasopressin mediates the response of the combined dexamethasone/CRH test in
hyper-anxious rats: Implications for the pathogenesis of affective disorders. Neuropsychopharmacology
26: 94-105 (2002)
19. Ströhle et al.: Induced panic attacks shift GABAA receptor modulatory neuroactive steroid
composition in patients with panic disorder. Archives of General Psychiatry 60: 161-168 (2003)
20. Páez-Pereda et al.: Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma
pathogenesis through a Smad/estrogen receptor crosstalk. Proceedings of the National Academy of
Sciences (PNAS) 3: 1034-1039 (2003)
21. Müller et al.: Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior
and hormonal adaptation to stress. Nature Neuroscience 6: 1100-1107 (2003)
22. Oshima et al.: Altered serotonergic neurotransmission but normal
hypothalamic-pituitary-adrenocortical axis activity in mice chronically treated with the
corticotropin-releasing hormone receptor type 1 antagonist NBI 30775. Neuropsychopharmacology 28:
2148-2159 (2003)
23. Schmidt et al.: Essential role of the unusual DNA-binding motif of BAG-1 for inhibition of the
glucocorticoid receptor. Journal of Biological Chemistry 278: 4926-4931 (2003)
24. Holsboer: CRH-modulators and depression. Current Opinion in Investigational Drugs 4: 46-50
(2003)
25. Uhr et al.: Differential enhancement of antidepressant penetration into the brain in mice with
abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biological Psychiatry 54: 840-846 (2003)
26. Murgatroyd et al.: Impaired repression at a vasopressin promoter polymorphism underlies
overexpression of vasopressin in a rat model of trait anxiety. Journal of Neuroscience 24: 7762-7770
(2004)
27. Binder et al.: Polymorphisms in FKBP5 are associated with increased recurrence of depressive
episodes and rapid response to antidepressant treatment. Nature Genetics 36:1319-1325 (2004)
28. Rüegg et al.: Cofilin 1 is revealed as inhibitor of glucocorticoid receptor by creation and analysis of
hormone-resistant cells. Molecular and Cellular Biology 24: 9371-9382 (2004)
29. Vila et al.: Sonic hedgehog regulates CRH signal transduction in the adult pituitary. FASEB
19:281-283 (2005)
30. De Kloet et al.: Stress and the brain: from adaptation to disease. Nature Reviews Neuroscience 6:
463-475 (2005)
31. Refojo et al.: CRH activates ERK1/2 MAPK in specific brain areas. Proceedings of the National
Academy of Sciences (PNAS) 102: 6183-6188 (2005)
32. Wochnik et al.: FK506-binding proteins 51 and 52 differentially regulate dynein interaction and
nuclear translocation of the glucocorticoid receptor in mammalian cells. Journal of Biological Chemistry
280: 4609-4616 (2005)
33. Müller and Holsboer: Mice with mutations in the HPA-system as models for symptoms of
depression. Biological Psychiatry 59: 1104-1115 (2006)
34. Binder and Holsboer: Pharmacogenomics and antidepressant drugs. Annals of Medicine 38: 82-94
(2006)
35. Lucae et al.: P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with
major depressive disorder. Human Molecular Genetics 15: 2438-2445 (2006)
36. Arzt and Holsboer: CRF signaling: molecular specificity for drug targeting in the CNS. Trends in
Pharmacological Sciences 27: 531-538 (2006)
37. Barden et al.: Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31
region points to P2RX7 as a susceptibility gene to bipolar affective disorder. American Journal of
Medical Genetics 141B: 374-382 (2006)
38. Winkelmann et al.: Genome-wide association study of restless legs syndrome identifies common
variants in three genomic regions. Nature Genetics 39: 1000-1006 (2007)
39. Carbia-Nagashima et al.: RSUME, a small RWD-containing protein, enhances SUMO conjugation
and stabilizes HIF-1alpha during hypoxia. Cell 131: 309-323 (2007)
40. Uhr et al.: Polymorphisms in the drug-transporter gene ABCB1 predict antidepressant treatment
response in depression. Neuron 57: 203-209 (2008)
41. Holsboer, F.: How can we realize the promise of personalized antidepressant medicines? Nature
Reviews Neuroscience 9: 638-646 (2008)
42. Hennings et al.: Clinical characteristics and treatment outcome in a representative sample of
depressed inpatients - Findings from the Munich Antidepressant Response Signature (MARS) project.
Journal of Psychiatric Research 43: 215-229 (2009)
43. Lu, A., Steiner, M. et al.: Conditional CRH overexpressing mice: an animal model for stress-elicited
pathologies and treatments that target the central CRH system. Molecular Psychiatry 13:1028-1042
(2008)
44. Kimura et al.: Conditional CRH overexpression in the mouse brain enhances REM sleep. Molecular
Psychiatry 15:154-165 (2010)
45. Rupprecht et al.: Translocator protein (18 kDa) as a target for anxiolytics without
benzodiazepine-like side effects. Science 325: 490-493 (2009)
46. Yehuda, R. et al.: Gene expression patterns associated with PTSD following exposure to the
attacks on the World Trade Center attacks. Biological Psychiatry 66: 708-711 (2009)
47. Ising, M. et al.: A genomewide association study points to multiple loci that predict antidepressant
drug treatment outcome in depression. Archives of General Psychiatry 66: 966-975 (2009)
48. Murgatroyd, C. et al.: Dynamic DNA methylation programs persistent adverse effects of early-life
stress. Nature Neuroscience 12: 1559-1566 (2009)
49. Kohli et al.: Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and
a lifetime history of suicide attempts in depressed patients. Archives of General Psychiatry 67: 348-359
(2010)
50. Holsboer, F., Ising, M.: Stress hormone regulation: biological role and translation into therapy.
Annual Review of Psychology 61: 81-109 (2010)
51. Perisic et al.: Valproate and amitriptyline exert common and divergent influences on global and
gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacology
35: 792-805 (2010)
52. McMahon et al. and the BiGs Consortium: Meta-analysis of genome-wide association data
detects a risk locus for major mood disorders on chromosome 3p21.1 Nature Genetics 42:128-131
(2010)
53. Kloiber, S. et al.: Variations in tryptophan hydroxylase 2 linked to decreased serotonergic activity
are associated with elevated risk for metabolic syndrome in depression. Molecular Psychiatry 15:
736-747 (2010)
54. Kohli, M. et al.: The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron
70: 252-265 (2011)
55. Refojo, D. et al.: Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic
effects of CRHR1. Science 333:1903-1907 (2011)
56. Mehta, D. et al.: Using polymorphisms in FKBP5 to define biologically distinct subtypes of
posttraumatic stress disorder: evidence from endocrine and gene expression studies. Archives of
General Psychiatry 68: 901-910 (2011)
57. Filiou, M. et al.: Proteomics and metabolomics analyses of a trait anxiety mouse model reveals
divergent mitochondrial pathways. Biological Psychiatry 70: 1074-1082 (2011)
58. Zschocke, J. et al.: Antidepressant drugs diversely affect autophagy pathways in astrocytes and
neurons - dissociation from cholesterol homeostasis. Neuropsychopharmacology 36: 1754-1768 (2011)
59. Paez-Pereda, M. et al.: Corticotropin releasing factor receptor antagonists for major depressive
disorder. Expert Opinion on Investigational Drugs 20: 519-535 (2011)
60. Menke, A. et al.: Polymorphisms within the metabotropic glutamate receptor 1 gene are associated
witth depression phenotypes. Psychoneuroendocrinology 37: 565-575 (2012)
61. Ditzen, C. et al.: Cerebrospinal fluid biomarkers for major depression confirm relevance of
associated pathophysiology. Neuropsychopharmacology 37: 1013-1025 (2012)
62. Menke, A. et al.: Dexamethasone stimulated gene expression in peripheral blood is a sensitive
marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 37:
1455-1464 (2012)
63. Griebel, G., Holsboer, F.: Neuropeptide receptor ligands as drugs for psychiatric diseases: the end
of the beginning? Nature Reviews Drug Discovery 11: 462-478 (2012)
64. Schmidt, M. et al.: The prospect of FKBP51 as drug target. ChemMedChem 7: 1351-1359 (2012)
65. Wagner, K. et al.: Differences in FKBP51 regulation following chronic social defeat stress correlate
with individual stress sensitivity:
Influence of paroxetine treatment.
Neuropsychopharmacology 37: 2797-2808 (2012)
66. Zimmermann, N. et al.: Antidepressants inhibit DNA methyltransferase 1 through reducing G9a
levels. Biochemical Journal 448: 93-102 (2012)
67. Hausch, F., Holsboer, F.: Structural Biology: Snapshot of an activated peptide receptor. Nature
490: 492-493 (2012)
68. Hausch, F., Holsboer, F.: The seven pillars of molecular pharmacology Angewandte Chemie 51:
12172-12175 (2012)

69. Klengel, T. et al.: Allele-specific DNA demethylation in FKBP5: A molecular mediator of gene x
childhood trauma interactions. Nature Neuroscience 16:
33-41 (2013)
Zitationsvergleich

Laborjournal Heft 10/2006
Zitationsvergleich 2000-2003: Hormon- und Stoffwechselforschung
Laborjournal Heft 3/2006
Zitationsvergleich 2000-2002: Neurowissenschaften, klinischer Teil
Laborjournal Heft 1-2/2006
Zitationsvergleich 2000-2002: Neurowissenschaften, Nichtklinische Neurowissenschaften
Professor Florian Holsboer zählt in der Statistik des Institute of Scientific Information
(ISI) zu den 100 meist zitierten Neurowissenschaftlern weltweit

Professor Florian Holsboer hat aktuell einen Hirschfaktor von 97.

Bücher


Florian Holsboer: Biologie für die Seele – Mein Weg zur personalisierten Medizin
(Februar 2009, ISBN 978-406-58360-5), 2. Auflage Oktober 2009
Holsboer, Gründer, Benkert: Handbuch der Psychopharmakotherapie
(November 2007, ISBN-13: 978-3540204756)
Holsboer, von Friedl: Endlich glücklich – Wege aus der Depression
(Mai 2006, Hörbuch, ISBN-13: 978-3902533029)
Holsboer, Ströhle: Anxiety and Anxiolytic Drugs
(Juni 2005, ISBN-13: 978-3540225683)

Source: http://holsboer.de/PDF/Publikationen.pdf

Neuroenhancement

„Smart & Happy Pills“ – Wie geht das mit dem Neuro-Enhancement? Vorbemerkungen Die Versuchung sich selbst zu dopen ist groß. Zur Zeit der Entstehung dieses Arti-kels wurde in den Medien über systematisches und durch die Politik gefördertes Doping im Sport in Deutschland spekuliert. Vorher machte nicht nur Lance Armstrong Schlagzeilen, als er seine Doping-Beichte über längst

dentaleducation.uams.edu

UAMS Oral Health Clinic Patient Registration Form Patient Information: atient Information: Name _____________________________________________________________________________ Male or Female Date of birth _____________________ SSN ___________________ Referred by _________________________ Address _______________________________________________________________________

Copyright © 2010-2014 Health Drug Pdf